BioCentury
ARTICLE | Clinical News

ZPL-389: Phase IIa started

February 8, 2016 8:00 AM UTC

Ziarco began a double-blind, placebo-controlled, international Phase IIa trial to evaluate 30 mg oral ZPL-389 once daily for 12 weeks in about 120 patients with moderate to severe psoriasis. Ziarco ha...